Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-09-09

Clinical Trial Update: FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump [Phase 3]

View source ↗

Summary

Phase 3 trial comparing FIasp to Novolog in type 1 diabetes patients using a 670G insulin pump has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fiasp (insulin aspart)
  • NovoLog (insulin aspart)

Snippet

Sponsor: Texas Diabetes & Endocrinology, P.A. | Conditions: Type 1 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2020-09-09